Wei-Jie Wang

Wei-Jie Wang

Auto-generated profile, based on publicly available information

Wei-Jie Wang

Division of Nephrology, Department of Internal Medicine, Lo-Sheng Sanatorium and Hospital, Ministry of Health and Welfare, New Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2026 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
CWChung-An Wang
Chung-An Wang
WWWei-Jie Wang
Wei-Jie Wang
Jui-Yi ChenJui-Yi Chen
Jui-Yi Chen
YTYu-Heng Tseng
Yu-Heng Tseng
CCChung-Yi Cheng
Chung-Yi Cheng
VWVin-Cent Wu
Vin-Cent Wu
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are vulnerable to infections. While sodium-glucose cotransporter-2 (SGLT-2) inhibitors provide established cardiorenal benefits, their effects on infection remain unclear. This study aimed to evaluate the association between SGLT-2 inhibitors and the risks of severe sepsis, infection-related complications, and mortality in this population. We conducted a real-world, active-comparator, new-user cohort study using the U.S. Collaborative Network of TriNetX. Adults with CKD and T2D who initiated SGLT-2 inhibitors or DPP-4 inhibitors between 2018 and 2024 were included. Propensity score matching was applied to balance baseline characteristics. The primary outcome was severe sepsis; secondary outcomes included septic shock, mortality, hospitalization, pneumonia, urinary tract infection (UTI), and genital infection. After matching, 25,049 patients were included in each group. During 1 year of follow-up, SGLT-2 inhibitor use was associated with a lower risk of severe sepsis than DPP-4 inhibitor use (2.7% vs. 3.3%; HR, 0.81; 95% CI, 0.73-0.90). Risks of septic shock (HR, 0.83), mortality (HR, 0.72), hospitalization (HR, 0.90), pneumonia (HR, 0.77), and UTI (HR, 0.72) were reduced, whereas the risk of genital infection (HR, 1.93) was higher. No significant differences were observed in diabetic ketoacidosis or acidosis. Among patients with CKD and T2D, SGLT-2 inhibitor initiation was associated with lower risks of severe sepsis, infection-related outcomes, hospitalization, and mortality compared with DPP-4 inhibitor initiation, despite a higher risk of genital infection. These findings support SGLT-2 inhibitors as a core therapy with potential benefits extending beyond cardiorenal protection in this high-risk population.